Home / ELI Lilly & CO (LLY)
ELI Lilly & CO
Forward trial catalysts linked to LLY
CSA tracks 15 forward catalysts for ELI Lilly & CO across 8 assets, spanning Phase 3. The nearest is a readout expected Oct 2026 (month precision). Confidence across its tracked catalysts breaks down as 15 medium. Tracked indications include Type2 Diabetes Mellitus, Type 2 Diabetes, Diabetes Mellitus, Type 2, and 17 more.
LLY in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, ELI Lilly & CO has:
Forward catalysts by year
2026 · 32027 · 132028 · 142029 · 162030 · 42031 · 3
Every catalyst in the snapshot comes with its date, date confidence and source link.
49 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| imlunestrant | NCT04975308 | Phase 3 | Active, not recruiting | 2024-06-24 | Experimental | Eli Lilly and Company | Breast Neoplasms; Neoplasm Metastasis |
| mirikizumab | NCT04232553 | Phase 3 | Active, not recruiting | 2024-11-28 | Experimental | Eli Lilly and Company | Crohn's Disease |
| orforglipron | NCT05869903 | Phase 3 | Active, not recruiting | 2025-07-25 | Experimental | Eli Lilly and Company | Obesity; Overweight; Overweight or Obesity |
| lebrikizumab | NCT06280716 | Phase 3 | Active, not recruiting | 2025-09-25 | Experimental | Eli Lilly and Company | Atopic Dermatitis |
| lebrikizumab | NCT05559359 | Phase 3 | Active, not recruiting | 2026-01-14 | Experimental | Eli Lilly and Company | Atopic Dermatitis; Eczema |
| mirikizumab | NCT03519945 | Phase 3 | Active, not recruiting | 2026-03-04 | Experimental | Eli Lilly and Company | Ulcerative Colitis |
| retatrutide | NCT06260722 | Phase 3 | Active, not recruiting | 2026-08-27 | Experimental | Eli Lilly and Company | Diabetes Mellitus, Type 2 |
| retatrutide | NCT06297603 catalyst | Phase 3 | Active, not recruiting | 2026-10 | Experimental | Eli Lilly and Company | Type 2 Diabetes |
| dulaglutide | NCT06257966 | Phase 3 | Active, not recruiting | 2026-10-01 | Active comparator | Beijing Dongfang Biotech Co., Ltd. | Type2 Diabetes Mellitus |
| retatrutide | NCT06662383 catalyst | Phase 3 | Active, not recruiting | 2026-11 | Experimental | Eli Lilly and Company | Obesity |
| orforglipron | NCT06672549 catalyst | Phase 3 | Recruiting | 2027-02 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| dulaglutide | NCT07156539 | Phase 3 | Not yet recruiting | 2027-03-30 | Active comparator | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Type 2 Diabetes |
| lebrikizumab | NCT06526182 | Phase 3 | Active, not recruiting | 2027-04-25 | Experimental | Almirall, S.A. | Dermatitis, Atopic; Eczema |
| orforglipron | NCT07613307 catalyst | Phase 3 | Recruiting | 2027-05 | Experimental | Eli Lilly and Company | Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Diso… |
| retatrutide | NCT07232719 catalyst | Phase 3 | Active, not recruiting | 2027-07 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| orforglipron | NCT06972459 catalyst | Phase 3 | Active, not recruiting | 2027-08 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| orforglipron | NCT06972472 | Phase 3 | Active, not recruiting | 2027-08 | Experimental | Eli Lilly and Company | Obesity; Overweight; Type 2 Diabetes |
| orforglipron | NCT06993792 | Phase 3 | Active, not recruiting | 2027-08 | Experimental | Eli Lilly and Company | Obesity; Overweight; Type 2 Diabetes |
| orforglipron | NCT06948422 catalyst | Phase 3 | Active, not recruiting | 2027-09 | Experimental | Eli Lilly and Company | Hypertension |
| orforglipron | NCT06948435 | Phase 3 | Active, not recruiting | 2027-09 | Experimental | Eli Lilly and Company | Hypertension; Overweight or Obesity |
| orforglipron | NCT06952530 | Phase 3 | Active, not recruiting | 2027-09 | Experimental | Eli Lilly and Company | Hypertension |
| retatrutide | NCT07035093 catalyst | Phase 3 | Active, not recruiting | 2027-09 | Experimental | Eli Lilly and Company | Obesity; Overweight; Chronic Low Back Pain (CLBP) |
| imlunestrant | NCT05514054 catalyst | Phase 3 | Active, not recruiting | 2027-10 | Experimental | Eli Lilly and Company | Breast Neoplasms |
| olomorasib | NCT06119581 catalyst | Phase 3 | Recruiting | 2027-11 | Experimental | Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
| mirikizumab | NCT05509777 catalyst | Phase 3 | Recruiting | 2027-12 | Experimental | Eli Lilly and Company | Crohn's Disease |
| lebrikizumab | NCT05735483 catalyst | Phase 3 | Enrolling by invitation | 2027-12 | Experimental | Eli Lilly and Company | Atopic Dermatitis; Eczema |
| orforglipron | NCT06672939 catalyst | Phase 3 | Recruiting | 2027-12 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| dulaglutide | NCT06739122 catalyst | Phase 3 | Recruiting | 2027-12 | Experimental | Eli Lilly and Company | Type 2 Diabetes |
| eloralintide | NCT07282600 catalyst | Phase 3 | Recruiting | 2028-01 | Experimental | Eli Lilly and Company | Overweight; Obesity |
| orforglipron | NCT07202884 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Urinary Incontinence,Stress |
| eloralintide | NCT07321886 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| eloralintide | NCT07353931 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Osteoarthritis; Overweight or Obesity |
| eloralintide | NCT07369011 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Sleep Apnea, Obstructive; Obesity; Overweight |
| orforglipron | NCT07790861 | Phase 3 | Not yet recruiting | 2028-03 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| retatrutide | NCT06859268 | Phase 3 | Active, not recruiting | 2028-04 | Experimental | Eli Lilly and Company | Obesity |
| mirikizumab | NCT06937086 | Phase 3 | Recruiting | 2028-04 | Experimental | Eli Lilly and Company | Ulcerative Colitis; Obesity or Overweight |
| orforglipron | NCT07153471 | Phase 3 | Active, not recruiting | 2028-04 | Experimental | Eli Lilly and Company | Osteoarthritis |
| mirikizumab | NCT06937099 | Phase 3 | Recruiting | 2028-05 | Experimental | Eli Lilly and Company | Crohn's Disease; Obesity or Overweight |
| orforglipron | NCT07223593 | Phase 3 | Recruiting | 2028-06 | Experimental | Eli Lilly and Company | Peripheral Arterial Disease |
| eloralintide | NCT07392190 | Phase 3 | Recruiting | 2028-06 | Experimental | Eli Lilly and Company | Overweight; Obesity |
| lebrikizumab | NCT07542483 | Phase 3 | Recruiting | 2028-08 | Experimental | Almirall, S.A. | Nummular Eczema |
| retatrutide | NCT07357415 | Phase 3 | Active, not recruiting | 2028-10 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| retatrutide | NCT06383390 | Phase 3 | Active, not recruiting | 2029-02 | Experimental | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD) |
| olomorasib | NCT06890598 | Phase 3 | Recruiting | 2029-05 | Experimental | Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung |
| orforglipron | NCT07794579 | Phase 3 | Recruiting | 2029-08 | Experimental | Eli Lilly and Company | Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal |
| orforglipron | NCT07668336 | Phase 3 | Not yet recruiting | 2030-03 | Experimental | Eli Lilly and Company | Diabetes Mellitus, Type 2 |
| dulaglutide | NCT07668336 | Phase 3 | Not yet recruiting | 2030-03 | Active comparator | Eli Lilly and Company | Diabetes Mellitus, Type 2 |
| retatrutide | NCT07165028 | Phase 3 | Recruiting | 2030-08 | Experimental | Eli Lilly and Company | Metabolic Dysfunction-Associated Steatotic Liver Disease |
| mirikizumab | NCT04844606 | Phase 3 | Recruiting | 2030-12 | Experimental | Eli Lilly and Company | Ulcerative Colitis; Ulcerative Colitis Chronic; Inflammatory Bowel Diseases; Crohn's Disea… |
| orforglipron | NCT07241390 | Phase 3 | Recruiting | 2031-08 | Experimental | Eli Lilly and Company | Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease |
Every trial the CSA sample links to LLY's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Diabetes Mellitus, Type 2Type 2 DiabetesAtherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)ObesityOverweightChronic Low Back Pain (CLBP)Metabolic Dysfunction-Associated Steatotic Liver DiseaseOverweight or ObesityHypertensionOsteoarthritisUrinary Incontinence,StressPeripheral Arterial DiseaseAtherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseDiabetes MelletusGlucose Metabolism DisordersMetabolic DisordersNutritional and Metabolic DiseasesEndocrine System DiseasesFeeding BehaviorBehaviorFastingGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide ReceptorsReceptors, G-Protein-CoupledReceptors, Cell SurfaceMembrane ProteinsProteinsReceptors, PeptidePrediabetic StatePrehypertensionObesity, AbdominalBreast NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungType2 Diabetes MellitusAtopic DermatitisEczemaDermatitis, Atopic
and 7 more.
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →